Protection of piglets immunized with a cloned pseudorabies virus by ABDELWAHID, S. A. & ELJALII, IMA
   
   
Journal of the Hellenic Veterinary Medical Society
Vol. 56, 2005
 
  
  Protection of piglets immunized with a cloned
pseudorabies virus
ABDELWAHID S. Department of Preventive
Medicine, Faculty of
Veterinary Medicine,
University of Khartoum
ELJALII IMA Department of Preventive
Medicine, Faculty of
Veterinary Medicine,
University of Khartoum
https://doi.org/10.12681/jhvms.15090
 
  Copyright © 2017 S. A. ABDELWAHID, IMA
ELJALII 
   
  
   
To cite this article:
ABDELWAHID, S., & ELJALII, I. (2017). Protection of piglets immunized with a cloned pseudorabies virus. Journal of the
Hellenic Veterinary Medical Society, 56(4), 307-310. doi:https://doi.org/10.12681/jhvms.15090
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 21/02/2020 05:52:10 |
τ 
ΠΕΡΙΟΔΙΚΟ ΤΗΣ ΕΛΛΗΝΙΚΗΣ ΚΤΗΝΙΑΤΡΙΚΗΣ ΕΤΑΙΡΕΙΑΣ 2005,56(4): 307-310 
JOURNAL OF THE HELLENIC VETERINARY MEDICAL SOCIETY 2005,56(4): 307-310 
Ερευνητική 
Πειραματική αξιολόγηση της προ­
στασίας χοιριδίων με ένα στέλεχος 
του ίου της Ψευδόλυσσας 
Abdelwahid Saeed Ali1*, Isam Mohd Ali Eljalii1 
* Π Ε Ρ Ι Λ Η Ψ Η . Σκοπός της παρούσας έρευνας ήταν να μελετη­
θεί ο κλώνος (mAlp) του ίου της Ψευδόλυσσας (pseudorabies 
virus, PrV) ως ανοσογόνος παράγοντας για τη νόσου του 
Aujeszky's. Η παθογονικότητα, η ανοσογονικότητα και η δυνατό­
τητα προστασίας που προκαλείται από τον ιό είναι οι κύριοι στό­
χοι της παρούσας μελέτης. Χρησιμοποιήθηκε μια έμεση ELISA για 
τον προσδιορισμό των αντισωμάτων του ίου. Το στέλεχος (mAlp) 
αποδείχθηκε μη παθογόνο για χοιρίδια ηλικίας 3-4 εβδομάδων, 
στη δόση των 10 plaque forming unk (p.f.u.). Ο τίτλος των αντι­
σωμάτων στον ιό συγκρίθηκε με τη δόση ανοσοποίησης. Η δια­
φορά στον τίτλο του ίου για τη δόση ανοσοποίησης των 10 και 
10 p.f.u. δεν ήταν σημαντική (ρ<0.01), αλλά μεταξύ των δόσεων 
10 και 10 ήταν στατιστικά σημαντική (ρ<0.05). Μετά από την πει­
ραματική μόλυνση των ανοσοποιημένων ατόμων με το παθογόνο 
στέλεχος PrV-CD, παρατηρήθηκε ολική προστασία των χοιριδίων 
στη δόση ανοσοποίησης των 10 p.f.u. Ως συμπέρασμα προκύπτει 
ότι το μη παθογόνο στέλεχος PrV-mAlp θεωρείται υψηλής ανο-
σογονικότητας και προσδίδει υψηλή προστασία έναντι των παθο­
γόνων στελεχών και μπορεί να θεωρηθεί ως ιδανικό εμβολιακό 
στέλεχος έναντι της νόσου. 
Λέξεις ευρετηριασμου: Ψευδόλυσσα, κλώνος ιού, προστασία 
*Απόδοση της περίληψης στην ελληνική γλώσσα από Ε. Ξυλουρη, 
Τμήμα Ζωικής Παραγωγής, Γεωπονικό Πανεπιστήμιο Αθηνών, Ιε­
ρά Οδός 75, 118 55, Αθήνα. 
INTRODUCTION 
Pseudorabies virus (PrV), also known as Aujeszky's 
disease virus (ADV), an alphaherpesvirus, is the cause of 
fatal nervous infection in piglets, respiratory disease 
and growth retardation in feeder and reproductive 
problems in breeding pigs (Kluge et al., 1992). The 
neuropathogenesis of PrV in the pig had been 
investigated by several researchers (Wittmann et al., 
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1980; Kritas et al., 1994; Kritas et al., 1995). The 
immunogenicity of many PrV vaccine strains had also 
been studied in pigs and proven to induce high levels of 
virus neutralizing antibodies (Martin and Wardley, 
1987; Pensaert et al., 1990; Ferrari et al., 2000). 
However, many of them were unable to prevent 
completely the replication of the virulent virus (Martin 
and Wardley, 1987; Pensaert et al., 1990) and the 
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establishment of latency of the wild type virus (Cowen 
et al., 1990; Schoenbaum et al., 1990). Developed 
mutants of PrV, lacking the neurovirulence for pigs, 
tend to substitute for the conventional vaccines as they 
are considered safer and better defined at the molecular 
level (Pensaert et al., 1992; Stegeman et al., 1994; 
Ficinska et al., 2003). Reduction of clinical disease, 
immunological protection against reinfection, virus 
shedding after challenge, latency, reactivation have all 
been considered important factors in evaluating these 
vaccines (Stegeman et al., 1994; Kritas et al., 1995). 
The plaque-purified clone of PrV (mAlp) was 
previously confirmed as non-pathogenic, immunogenic 
and protective against virulent challenge in mice (Ali et 
al., 1998; Ali, 1999). The immunogenicity of this virus in 
piglets was proved to correlate with the route and 
antigen preparation (Ali et al., 2004). It was the 
objective of this study to determine the protective 
potentials of the cloned mAlp virus and investigate it as 
vaccine candidate against the disease. 
MATERIALS AND METHODS 
Viruses 
PrVs used in the study were: (/) PrV-mAlp: a plaque 
purified clone of PrV isolate, kindly provided by 
Professor Mohd Azmi (Putra University, Malaysia), 
used as an immunizing agent. This is basically a clone of 
a Malaysian PrV isolate, isolated during an outbreak of 
the disease in 1994, (//) PrV-CD: this is an American 
isolate of PrV, kindly provided by Professor Y.C. Zee 
(University of California-Davis, USA). This virus was 
confirmed as highly pathogenic for pigs (Ali, 1999) and 
hence used to challenge the immunized piglets. 
Piglets 
Thirty-two, 3-4 week-old piglets, obtained from PrV 
non-vaccinated dams, were kept in an experimental 
house and offered feed and water in independent 
groups. 
Virus preparation and purification 
Both vaccine and challenge viruses were propagated 
in Vero cells monolayers grown in Leibovitz's (L-15) 
medium, supplemented with 5% fetal bovine serum 
(FBS) 1% antibiotic-antimycotic and 1% anti-pleuro-
pneumonia- like organisms (anti-PPLO) agent. The 
viruses were purified from Vero cell cultures using 
sucrose gradient ultracentrifugation as described by 
Ben-Porat et al. (1974). 
Experimental design 
Thirty-two, 3-4 week-old piglets were divided into 
four groups namely A, B, C and D (eight piglets per 
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group). The piglets in groups A, Β and C were 
inoculated with 106, 107 and 108 plaque forming unit 
(p.f.u.) per piglet of PrV-mAlp intranasally (i.n.) 
respectively, while those in group D were given L-15 
medium as control. The clinical signs, rectal temperature 
and body weight were recorded. Nasal swabs and blood 
samples were collected at five days interval. Twenty-
five days later all animals were challenged with 108 p.f.u. 
per piglet of PrV-CD i.n. All these parameters were 
again determined after challenge. 
Virus detection in swine nasal swabs 
Nasal swabs were collected at day 3, 5, 7, 9 and 12 
post-challenge in 1 ml of ice-cold, serum free L-15 
medium, containing 8% antibiotic-antimycotic solution 
and 2% anti-PPLO agent in the 2 ml vial. The swabs 
were collected from all piglets in the group (8 piglets). 
These swabs were thoroughly squeezed in the media 
and the suspensions were then transferred to eppendorf 
tubes and spun at 3,000 rpm for 10 minutes at 4°C in a 
refrigerated centrifuge to remove any debris associated 
with the sample collection. The supernatants were then 
kept at -70 ° C before being tested for the virus by plaque 
assay. The plaque assay for virus detection in swine 
nasal swabs was performed as described by Ali (1999). 
ELISA for detection of serum antibody 
The indirect ELISA technique employed to measure 
the antibody titres in swine sera was conducted 
according to the well-established principles and 
protocols of Clark and Barbara (1987). The modifi­
cation made by Ali and Mohd-Azmi (1997) were also 
considered. These modifications include the incubation 
time and temperatures. 
Statistical analysis 
The statistical significance of differences between 
groups of data was determined using the two-tailed 
Student's unpaired t-test. 
RESULTS 
Pathogenicity of PrV-mAlp 
Following the primary inoculation of pigs with PrV-
mAlp, no clinical signs and mortality were observed 
(Table 1). No increase in rectal temperature or decrease 
in body weight were detected in piglets for any dose of 
inoculation. The virus shedding from nostrils of piglets 
was detected as maximum up to day 3, 5 and 7 post-
inoculation in the animals inoculated with dose 106,107 
and 108 p.f.u. per piglet, respectively. 
Immunogenicity and protection conferred by PrV-
mAlp strain 
The ELISA antibody (Ab) response induced in 
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Table 1: 
Animal 
group 
A 
Β 
C 
D 
Mortality in piglets immunized with different doses of PrV-mAlp and challenged with PrV-CD 
Dose of immunization 
(with PrV-mAlp) 
106 p.f.u. 
107 p.f.u. 
108 p.f.u. 
Control 
Mortality (%) after Mortality (%) after 
inoculation with PrV-mAlp challenge with PrV-CD 
0/8 (0) 0/8 (0) 
0/8 (0) 0/8 (0) 
0/8 (0) 0/8 (0) 
0/8 (0) 6/8 (75) 
Challenge was performed at 25 days after vaccination with lx 108 p.f.u. per piglet. 
Both immunization and challenge were via i.n. route. The control group of piglets was inoculated with L-15 tissue culture medium. 
Table 2: Average rectal temperature, virus titre and increase in body weight at day 4 post-challenge of piglets 
Animal 
group 
A 
Β 
C 
D 
Dose of immunization 
(with PrV-mAlp) 
106 p.f.u. 
107 p.f.u. 
108 p.f.u. 
Control 
Rectal 
temperature* 
39.4±0.09 
38.8±0.12 
38.6±0.21 
40.2±0.17 
Virus 
detection 
+ 
-
-
+ 
Increase in 
body weght** 
2.16±1.24 
2.87±1.08 
3.52±1.34 
2.08 ±1.25 
* Rectal temperature (°C±s.d.) 
**Body weight (Kg), the increase in body weight as compared to day of challenge 
+ = virus detected; -= virus not detected 
piglets inoculated with different doses of PrV-mAlp is 
demonstrated in Figure 1. It was observed to be dose 
dependent. Peak Ab responses were observed at day 25 
post inoculation in all groups of piglets. Following 
challenge, total clinical protection was observed in all 
groups, except for the control where 6/8 (75%) of the 
piglets died (Table 1). The death of these piglets 
continued up to day 7 post-challenge. The shedding of 
the virulent virus after challenge was dependent on the 
dose of immunization and lasted up to day 4 and 3 p.i. 
for the immunizing doses 106 and 107 p.f.u. respectively. 
The virus was not detected in piglets immunized with 
108 p.f.u. per piglet of PrV-mAlp (Table 2). ELISA-Ab 
responses continued to rise after challenge till they 
peaked at day 55 p.i. (30 post-challenge) for the doses 
106 and 107 p.f.u. per piglet and day 60 p.i. (35 post-
challenge) for the dose 108 p.f.u. per piglet (Figure 1). 
DISCUSSION 
The present study is focused on the ability of a 
plaque purified clone of PrV, termed mAlp, to serve as 
an immunizing agent against virulent challenge in 
piglets. The results obtained indicated that the clone 
virus is safe and potentially immunogenic and protective 
as well as non pathogenic for pigs even at the dose 108 
p.f.u. This substantiates our results published previously 
(Ali et al., 1998; Ali, 1999), when similar findings were 
obtained upon testing the immunogenicity of the same 
virus in mice. In contrast, PrV-CD (the challenge virus) 
was proved pathogenic for piglets causing 60% mortality 
10 15 20 25 30 35 40 45 50 55 
Days p.i. 
• 10°p.f.u. - 107p.f.u. — • — 10a p.f.u. 
Figure 1. Antibody responses in piglets immunized with different 
doses of PrV-mAlp and challenged with PrV-CD 
Data points represents the antibody titres 
(geometrìe mean±s.d.; n=5) 
when inoculated with >108 p.f.u. per piglet (Ali, 1999). 
The data obtained also revealed that the antibody 
response to the virus is dose dependent with a significant 
increase (p<0.05) in the antibody titres, when piglets 
immunized with the dose 108 p.f.u. compared to lower 
doses. In previous report, similar finding was docu-
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mented (Ali and Mohd-Azmi, 1997). The present study 
also showed that PrV-mAlp is highly immunogenic and 
confers a 100% clinical protection against the challenge 
with a lethal dose of PrV-CD at the immunization dose 
> 106 p.f.u. per piglet. However, total clinical and 
virological protection was obtained at the immunization 
dose 108 p.f.u. per piglet where the virus was not 
detected in piglets nostrils after challenge when 
immunized with 108 p.f.u. per piglet of PrV-mAlp. In 
some previous reports, it was confirmed that although 
most vaccines were clinically protective, they did not 
prevent virus shedding following experimental or natural 
challenge (Pensaert et al., 1990; Vannier et al., 1991). 
It was previously established that the loss of PrV 
virulence is mostly accompanied by too much loss of 
immunogenicity (Pensaert et al., 1992). This is not true 
for the clone PrV-mAlp that appeared as potent 
immunogen, but also avirulent for its natural host. 
Based on that ground, PrV-mAlp can be suggested as 
a good and safe vaccine against the PrV infection in 
swine. • 
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